Christopher Hourigan, MD, DPhil
Genomic profiling provides evidence of measurable residual disease (MRD) in patients with acute myeloid leukemia (AML) and may help guide the choice of a preconditioning regimen in those who are at risk of relapse after undergoing allogeneic hematopoietic cell transplantation (alloHCT), according to findings presented at the 2019 European Hematology Association Congress.
Table. Custom Gene Panel for Detection of MRD in AML1
In their supplementary study, Hourigan and colleagues evaluated 188 whole blood samples from participants in the BMT CTN trial, collected equally from patients who received RIC and MAC who were well matched for other baseline characteristics.
... to read the full story